{$ZY} Zymergen reports Q3 EPS (96c), consensus (67c) Reports Q3 revenue $4.1M, consensus $4.49M. Total operating expenses for Q3 $99.3M, including total restructuring charges of $21.2M and a reversal of accrued performance bonuses of approximately $9.4M. Net loss for Q3 was $98M. The company's cash and cash equivalents were $496.2M as of September 30, 2021, excluding restricted cash of $10.8M.